Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Profit After Tax came in at -$16.4 million in Q1 2026, down 19.75% year-on-year from -$20.4 million in Q1 2025, and down 28.63% on a QoQ basis from -$12.7 million in Q4 2025.
Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Profit After Tax data on file, last reported at -$16.4 million in Q1 2026.
- On a quarterly basis, Profit After Tax fell 19.75% year-over-year to -$16.4 million in Q1 2026; TTM through Mar 2026 was -$51.0 million, a 39.43% decrease from a year earlier, with the FY2025 full-year figure at -$48.3 million, down 75.36% from the prior year.
- Profit After Tax for Q1 2026 stood at -$16.4 million, down from -$12.7 million in the prior quarter.
- Over the last five years, Profit After Tax for IKT reached as high as -$4.2 million in Q4 2023 and fell as low as -$16.4 million in Q1 2026.
- Historically, Profit After Tax has averaged -$7.6 million across 5 years, with a median of -$5.0 million in 2024.
- Across the five-year window, Profit After Tax gained 15.13% in 2022 and tumbled 194.19% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$4.3 million in 2022, then increased by 2.36% to -$4.2 million in 2023, then sank by 190.4% to -$12.1 million in 2024, then slipped by 4.96% to -$12.7 million in 2025, then dropped by 28.63% to -$16.4 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$16.4 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | -16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.38 Mn |
| Dec 31, 2025 | -12.73 Mn |
| Sep 30, 2025 | -11.93 Mn |
| Jun 30, 2025 | -9.92 Mn |
| Mar 31, 2025 | -13.68 Mn |
| Dec 31, 2024 | -12.13 Mn |
| Sep 30, 2024 | -5.78 Mn |
| Jun 30, 2024 | -4.96 Mn |
| Mar 31, 2024 | -4.65 Mn |
| Dec 31, 2023 | -4.18 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | -5.78 Mn |
| Mar 31, 2023 | -4.48 Mn |
| Dec 31, 2022 | -4.28 Mn |
| Sep 30, 2022 | -4.49 Mn |
| Jun 30, 2022 | -4.64 Mn |
| Mar 31, 2022 | -4.64 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | -2.64 Mn |